Kolon TissueGene Stocks Hit 3-Day Limit-Down After US Phase 3 Trial Failure
Kolon TissueGene stocks hit the daily limit-down for three days from May 21 to May 23 after its arthritis drug failed a US Phase 3 trial. The stock closed at 21,050 won on May 23, down 29.95%, after trial TGC-15302 for TG-C treatment did not show statistical significance versus placebo in Visual
Kolon TissueGene-1.90%
LucasBennett·07-23 06:34
